Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

178
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
178
Pneumonia IV: Management01:28

Pneumonia IV: Management

323
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
323
Sputum Studies II: Culture and Sensitivity01:20

Sputum Studies II: Culture and Sensitivity

308
Description
Sputum culture and sensitivity is a medical procedure used to diagnose bacterial infections in the respiratory tract and select the most appropriate antibiotics for treatment. This process involves analyzing sputum samples of thick and opaque secretions produced in the lungs and airways. These samples are collected from patients and then sent to the laboratory for analysis.
The test can identify various pathogens responsible for respiratory infections, including Streptococcus,...
308

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: "Sleep quality is influenced by multiple factors and cannot be reduced to the volume of pineal gland calcification".

Arquivos de neuro-psiquiatria·2026
Same author

Does fixation of medium sized posterior malleolus fragment in ankle fractures yield superior outcomes than no-fixation? A systematic review and meta-analysis.

Foot (Edinburgh, Scotland)·2026
Same author

Retrograde intramedullary nailing versus locked plate fixation for distal femur fractures: A systematic review and meta-analysis of randomised controlled trials only.

Injury·2026
Same author

Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection.

Journal of viral hepatitis·2026
Same author

Genome-Wide Association of ST, K-, and O-Locus Diversity with Virulence in Indian Klebsiella pneumoniae via Targeted Phenotypic Validation.

Current microbiology·2026
Same author

Enhancing 7T MRI for deep brain stimulation with deep-learning based image reconstruction and dynamic parallel transmission.

NeuroImage. Clinical·2026

Related Experiment Video

Updated: Jun 28, 2025

Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia
05:39

Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia

Published on: May 26, 2023

1.5K

Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.

Vishal Patel1, Bethany Levick2, Stephen Boult2

  • 1GSK House, 980 Great West Road, TW8 9GS, Brentford, Middlesex, UK.

BMC Infectious Diseases
|April 22, 2024
PubMed
Summary
This summary is machine-generated.

Early COVID-19 treatment with monoclonal antibodies (mAbs) showed low hospitalization and death rates. These outcomes remained consistent across Omicron subvariant periods, including BA.1, BA.2, and BA.5.

Keywords:
COVID-19Monoclonal antibodyOmicronSotrovimab

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.7K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

2.9K

Related Experiment Videos

Last Updated: Jun 28, 2025

Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia
05:39

Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia

Published on: May 26, 2023

1.5K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.7K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

2.9K

Area of Science:

  • Infectious Diseases
  • Virology
  • Clinical Medicine

Background:

  • The effectiveness of early COVID-19 treatments against evolving SARS-CoV-2 variants is uncertain.
  • This study examines outcomes of patients treated with monoclonal antibodies (mAbs) during Omicron subvariant predominance.

Purpose of the Study:

  • To assess the clinical outcomes of COVID-19 patients treated with a specific monoclonal antibody (presumed sotrovimab) during different Omicron subvariant waves.
  • To evaluate the impact of Omicron subvariants (BA.1, BA.2, BA.5) on treatment effectiveness.

Main Methods:

  • Retrospective cohort study of 10,096 patients receiving mAbs (presumed sotrovimab) in England, January-July 2022.
  • Data analyzed from Hospital Episode Statistics, focusing on COVID-19-attributable hospitalizations and all-cause mortality.
  • Subgroup analyses included patients with severe renal disease and active cancer.

Main Results:

  • A total of 1.0% of patients experienced COVID-19-attributable hospitalization; 0.3% died from any cause.
  • Hospitalization rates were consistent across periods dominated by Omicron BA.1, BA.2, and BA.5 subvariants.
  • No significant differences in outcomes were observed across subgroups or Omicron subvariant periods.

Conclusions:

  • Monoclonal antibody treatment for COVID-19 resulted in low rates of hospitalization and death.
  • Treatment effectiveness remained consistent despite the emergence of Omicron BA.1, BA.2, and BA.5 subvariants.
  • Findings support the continued use of mAbs in managing COVID-19, even with variant evolution.